千金药业：获准发行股份及支付现金购买资产

Core Viewpoint - The company plans to acquire a 28.92% stake in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and a 68.00% stake in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of issuing shares and cash payments [1] Summary by Relevant Sections - The company received approval from the China Securities Regulatory Commission on September 12, 2025, for the issuance of 51,444,900 shares to specific investors for the asset acquisition [1] - The share issuance for asset acquisition must strictly follow the application documents submitted to the Shanghai Stock Exchange and is required to be completed within 12 months [1]